Exacerbation Profile and Risk Factors in a Type-2–Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes-Reference-Cited by-同舟云学术

Exacerbation Profile and Risk Factors in a Type-2–Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes

Published:2022-09-01 Issue:5 Volume:206 Page:545-553
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

McDowell P. Jane¹^ORCID,Busby John¹,Hanratty Catherine E.¹^ORCID,Djukanovic Ratko²^ORCID,Woodcock Ashley³^ORCID,Walker Samantha⁴,Hardman Timothy Colin⁵^ORCID,Arron Joseph R.⁶^ORCID,Choy David F.⁶,Bradding Peter⁷^ORCID,Brightling Chris E.⁷^ORCID,Chaudhuri Rekha⁸^ORCID,Cowan Douglas⁹,Mansur Adel H.¹⁰^ORCID,Fowler Stephen J.³,Diver Sarah E.⁷^ORCID,Howarth Peter²,Lordan James¹¹,Menzies-Gow Andrew¹²^ORCID,Harrison Timothy¹³,Robinson Douglas S.¹⁴,Holweg Cecile T. J.⁶,Matthews John G.¹⁵,Pavord Ian D.¹⁶^ORCID,Heaney Liam G.¹^ORCID

Affiliation:

1. Center for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University, Belfast, United Kingdom;

2. School of Clinical and Experimental Sciences, University of Southampton, National Institute for Health and Care Research (NIHR) Southampton Biomedical Research Center, Southampton, United Kingdom;

3. Manchester Academic Health Science Center and NIHR Manchester Biomedical Research Center, Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester, United Kingdom;

4. Asthma UK and British Lung Foundation Partnership, London, United Kingdom;

5. Niche Science and Technology Ltd., Richmond, United Kingdom;

6. Genentech Inc., San Francisco, California;

7. Department of Respiratory Sciences, Institute for Lung Health and Leicester NIHR Biomedical Research Center, University of Leicester, Leicester, United Kingdom;

8. Gartnavel General Hospital, Glasgow and University of Glasgow, Glasgow, United Kingdom;

9. NHS Greater Glasgow and Clyde, Stobhill Hospital, Glasgow, United Kingdom;

10. University of Birmingham and Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom;

11. the Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, United Kingdom;

12. Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, the University of Manchester, Royal Brompton and Harefield Hospitals, London, United Kingdom;

13. Nottingham Respiratory NIHR Biomedical Research Center, University of Nottingham, Nottingham, United Kingdom;

14. University College Hospitals NHS Foundation Trust, London, United Kingdom;

15. 23andMe, Sunnyvale, California; and

16. Oxford Respiratory NIHR Biomedical Research Center, Nuffield Department of Medicine, the University of Oxford, Oxford, United Kingdom

Funder

Medical Research Council

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Link

https://www.atsjournals.org/doi/pdf/10.1164/rccm.202201-0129OC

Reference28 articles.

1. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

2. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry

3. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry

4. Incidence and US Costs of Corticosteroid-Associated Adverse Events: A Systematic Literature Review

5. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Larger Mediastinal Lymph Nodes Are Associated with Worse Lung Function in Persistent Asthma;American Journal of Respiratory and Critical Care Medicine;2024-02-01

2. Characterization and inhibition of inflammasome responses in severe and non-severe asthma;Respiratory Research;2023-12-04

3. Promising treatment biomarkers in asthma;Frontiers in Drug Safety and Regulation;2023-11-07

4. Phenotyping the Responses to Systemic Corticosteroids in the Management of Asthma Attacks (PRISMA): protocol for an observational and translational pilot study;BMJ Open Respiratory Research;2023-11

5. Biomarker-guided withdrawal of inhaled corticosteroids in asthma patients with a non-T2 inflammatory phenotype – a randomized controlled trial study protocol;BMC Pulmonary Medicine;2023-10-04